2026年10月2日 11:13 ET 发布 · 更新于 1 个月前 · 1 个来源
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC Markets
·
原始报道
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
原文